Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis
20. juli 2026 oppdatert av: Ron Beloosesky MD
Apixaban Versus Enoxaparin for Thromboprophylaxis After Delivery
The purpose of this study is to compare the use of oral apixaban to subcutaneous enoxaparin for venous thromboembolism (VTE) prophylaxis in postpartum women at high risk for VTE.
The primary goal is to evaluate medication adherence rates and patient satisfaction with the treatment.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Venous thromboembolism (VTE) is a leading cause of pregnancy-related morbidity and mortality.
Current guidelines recommend pharmacologic thromboprophylaxis with low-molecular-weight heparin (LMWH), such as enoxaparin, for postpartum women with increased risk factors.
However, common patient complaints related to enoxaparin include injection site reaction, pain, bruising, bleeding, nausea, vomiting, and cost.
Oral anticoagulation therapy, such as apixaban (an oral factor Xa inhibitor), could obviate many of these negative effects.This single-center, prospective, open-blinded randomized controlled trial aims to investigate the use of apixaban versus enoxaparin for VTE prophylaxis in the postpartum period.
Eligible postpartum women (after vaginal or cesarean delivery) with high risk for VTE will be randomized in a 1:1 ratio.
Studietype
Intervensjonell
Registrering (Antatt)
150
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Nira Gridish
- Telefonnummer: +972503027855
- E-post: n_gridish@rambam.health.gov.il
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years.
- After Vaginal or C/S delivery.
- Need prophylactic treatment in a preventive dose.
- Presence of one or more high risk factors: Active infection, IBD, Heart disease, Type 1 diabetes with nephropathy, IV drug user, Surgical operation in Postpartum period, Emergency cesarean section.
OR presence of 2 low risk factors: Age > 35, post-partum hemorrhage > 1000 ml, Cesarean section, Hysterectomy, BMI > 30, Multiparity- Third birth or more, Active Smoking, Obstetric complications in current pregnancy (including preeclampsia, preterm birth before 37 weeks, active infection including chorioamnionitis, prolonged labor over 24 hours), Twin birth, Immobility, Large varicose veins, Stillbirth
Exclusion Criteria:
- Breast feeding.
- Predispose to hypercoagulability
- Familial history of VTE.
- Antiphospholipid syndrome (APS).
- Prior VTE.
- Anticoagulant treatment before or during pregnancy.
- BMI > 40
- History of severe renal or hepatic disease.
- Use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors.
- Known diagnosis of bleeding dyscrasia (eg, von Willebrand disease).
- Spinal/epidural hematoma or spinal puncture.
- Active pathological bleeding or high risk of bleeding.
- Hemoglobin > 9 mg/dl before the delivery.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Apixaban
Apixaban.
2.5 mg administered orally twice a day
|
Apixaban.
2.5 mg administered orally twice a day
Andre navn:
|
|
Aktiv komparator: Enoxaparin
Enoxaparin. 40 mg (or 60 mg for weight > 91 kg) administered subcutaneously once a day
|
Enoxaparin 40 mg (or 60 mg for weight > 91 kg) administered subcutaneously once a day
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
General Treatment Convenience Assessed by a Study-Specific Patient Satisfaction Questionnaire
Tidsramme: up to 6 weeks postpartum
|
Patient-reported treatment convenience assessed using a study-specific questionnaire.
The primary measurement is an 11-point general convenience Visual Analog Scale (VAS) where patients rate the overall convenience of their assigned post-partum anticoagulant treatment (oral vs. subcutaneous) from 0 ("Not convenient at all") to 10 ("Very convenient").
Higher scores indicate a higher level of treatment convenience.
The outcome also incorporates a categorical question evaluating whether the treatment was easy to take/receive (categorized as: Agree, Neutral, Disagree).
|
up to 6 weeks postpartum
|
|
Medication Adherence Rate Assessed by Patient Self-Report
Tidsramme: Up to 6 weeks postpartum
|
Adherence to the prescribed thromboprophylaxis regimen, assessed via patient self-report within the study questionnaire.
Adherence is evaluated through targeted categorical questions regarding compliance: (1) whether the patient faced difficulties remembering to take the medication, and (2) whether any dose was missed during the hospitalization period.
Responses are categorized as "Agree," "Neutral," or "Disagree."
The outcome will be reported as the percentage of patients who demonstrated adherence (i.e., no missed doses and no memory difficulties) versus non-adherent patients
|
Up to 6 weeks postpartum
|
|
Treatment-Related Pain Intensity Assessed by a Visual Analog Scale (VAS)
Tidsramme: Up to 6 weeks postpartum
|
Intensity of pain specifically associated with the administration of the assigned anticoagulant therapy.
This is evaluated using an 11-point Visual Analog Scale (VAS) embedded in the questionnaire.
Patients who report experiencing treatment-related pain rate its intensity on a scale ranging from 0 ("No pain at all") to 10 ("Unbearable pain").
Lower scores indicate lower pain levels and better treatment tolerance.
|
Up to 6 weeks postpartum
|
|
Patient Treatment Preference and Recommendation Assessed by Self-Report
Tidsramme: Up to 6 weeks postpartum
|
Patient preference for future short-term preventative treatment options based on their experience during the clinical trial.
Patients select their preferred route of administration from three options: Oral tablets, Subcutaneous injections, or No preference.
Additionally, the assessment includes a categorical question on whether the patient would recommend their assigned treatment to another person (Categorized as: Agree, Disagree, Do not know).
Results will be presented as the proportion (%) of patients in each preference and recommendation category.
|
Up to 6 weeks postpartum
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Venous Thromboembolism (VTE)
Tidsramme: up to 6 weeks postpartum
|
Occurrence of VTE event
|
up to 6 weeks postpartum
|
|
Incidence of major bleeding and bleeding events
Tidsramme: up to 6 weeks postpartum
|
Major bleeding and bleeding events defined according to the International Society on Thrombosis and Hemostasis (ISTH) criteria.
|
up to 6 weeks postpartum
|
|
Decrease in hemoglobin values
Tidsramme: From baseline (admission to labor and delivery unit) up to the day of postpartum discharge (typically 2 to 5 days)
|
Comparison of the decrease in hemoglobin levels between the apixaban and enoxaparin study groups.
The baseline value is defined as the hemoglobin level measured via complete blood count (CBC) upon the patient's admission to the labor and delivery unit.
The final value is the hemoglobin level measured on the day of her clinical discharge from the postpartum ward.
The decrease will be calculated for each participant by subtracting the discharge value from the baseline value.
|
From baseline (admission to labor and delivery unit) up to the day of postpartum discharge (typically 2 to 5 days)
|
|
Incidence of adverse events
Tidsramme: up to 6 weeks postpartum
|
Patient-reported side effects assessed via a participant questionnaire.
|
up to 6 weeks postpartum
|
|
ACTS Burden Score
Tidsramme: Up to 6 weeks postpartum
|
Treatment burden associated with assigned anticoagulant therapy, assessed using the ACTS Burden subscale.
The subscale contains 5 items with a total score ranging from 5 to 25. Lower scores indicate lower perceived treatment burden and greater treatment satisfaction.
|
Up to 6 weeks postpartum
|
|
ACTS Benefit Score
Tidsramme: Up to 6 weeks postpartum
|
Perceived benefit of assigned anticoagulant therapy, assessed using the Anti-Clot Treatment Scale (ACTS) Benefit subscale.
The ACTS Benefit subscale consists of 3 items evaluating patient perception of treatment effectiveness and reassurance.
Total scores range from 3 to 15.
Higher scores indicate greater perceived treatment benefit.
|
Up to 6 weeks postpartum
|
|
Treatment Convenience Score
Tidsramme: Up to 6 weeks postpartum
|
Participant-reported convenience of assigned anticoagulant therapy, assessed using a Visual Analog Scale (VAS).
Scores range from 0 to 10, where 0 represents "not convenient at all" and 10 represents "extremely convenient."
Higher scores indicate greater treatment convenience.
|
Up to 6 weeks postpartum
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. juli 2026
Primær fullføring (Antatt)
1. april 2027
Studiet fullført (Antatt)
1. april 2027
Datoer for studieregistrering
Først innsendt
22. mars 2026
Først innsendt som oppfylte QC-kriteriene
20. juli 2026
Først lagt ut (Faktiske)
21. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
21. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
20. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 0495-24RMB
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .